A Los Angeles–based law firm has filed a class action lawsuit on behalf of thousands of Blue Cross beneficiaries living with hepatitis C virus (HCV). The suit alleges that the health care service provider is intentionally and illegally denying treatment for the liver disease to limit its own financial burdens, according to a press release from Gianelli & Morris, the firm that brought the suit.

Specifically, the lawsuit speaks to Blue Cross’s limitation of Harvoni (ledipasvir/sofosbuvir), one of Gilead Sciences’ newest—and most expensive—hep C cure combos. It alleges that thousands of people have been denied the drug since it came out in 2014 because, according to insurer denial letters, it was “not medically necessary” for those people to receive the $94,000 treatment before serious liver damage took hold.

Current guidelines from both the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America state that HCV treatment is best administered in the early stages of an infection, preferably before liver fibrosis and cirrhosis, or liver scarring, begin. However, the California lawsuit claims that Blue Cross has been systematically denying all requests for Harvoni and other hep C treatments from patients who have not scored an F3 (severe fibrosis) or an F4 (end-stage fibrosis) score on liver function tests.

Ultimately, the lawsuit seeks to stop Blue Cross limiting the drug and force it to compensate all beneficiary members who have been harmed by its actions.